Resources

In this blog, Emily Klein reflects on the importance of Rare Disease Day in bringing visibility to those affected by a rare condition and serving as a focal point for advocacy in this space.

With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.

The UK’s life sciences and biotech sector has long been recognised for its scientific excellence, vibrant innovation and dynamic startup culture around the globe. In the past year, interest in our business ecosystem from international partners has markedly accelerated.

In this guest blog, Richard Turner, Senior Managing Director at FTI Consulting, discusses how licence and collaboration agreements in life sciences can create significant tax consequences.

It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

A bumper update today as we highlight the critical importance of building UK capability and innovation leadership as geopolitics continues to provide uncertainty.

What an incredible night! Last Thursday, we welcomed a record 780 of you to the Roundhouse for the 2026 BIA Gala Dinner. It was a powerful reminder of the strength, resilience and sheer brilliance of our community.

In this blog, Saqib Lal, Head of Content at BIA, reflects on a stellar Gala Dinner. He describes it as a moment to pause and recognise the extraordinary people who make the UK life sciences sector a global powerhouse. This year, as a record 780 guests gathered at the iconic Roundhouse for an evening that demonstrated renewed ambition and positivity. 

The BioIndustry Association (BIA) has recognised the achievements of Dr Ruth McKernan CBE, neuroscientist, entrepreneur, investor and former Chair of the BIA Board, with the inaugural Chiswell Lifetime Achievement Award.

Our UK biotech financing 2025 report is out today, including data and commentary on how the biotech investment landscape fared last year. 2025 was a brutal year for the sector, but an upswing in deal numbers going into 2026 and recent capital injections give good reason to be optimistic.

With a number of unprecedented leaks, speculation and media briefings indicating potential wide ranging and significant tax rises, in the end the 2025 Autumn Budget seemed to be one of restraint and headline rates remained untouched.

J.P. Morgan’s healthcare conference may be wrapped up, but it has set some tangible momentum and without doubt a more buoyant mood for global life sciences going into 2026.

This week JPM kicks off in San Francisco with BIA hosting a UK Reception. A significant week for BIA too with the long-awaited announcement of our new CEO.

Happy New Year to all our BIA members and collaborators. We hope that the break has provided an opportunity for a refresh, ready for a jam-packed 2026.

BIA thought leadership takes centre stage with two key reports published: last week saw the release of 'From innovation to impact: unlocking patient access to innovative rare disease medicines', and today 'UK cell and gene therapy: driving efficiencies and innovation' celebrates real-world UK success.

In this analysis by Dr Martin Turner, Director of Policy and External Affairs, BIA, discover how the 2025 Budget could supercharge UK life sciences scale-ups with major investment incentives - while also highlighting potential risks from rising business rates.

Read our statement welcoming the Chancellor’s extended venture investment tax incentives and support for employee share options, as well as the prioritisation of tax and spending decisions in areas where the UK can lead and win.